Purwowiyoto Sidhi Laksono, Prawara Ananta Siddhi
Cardiac Catheterization Laboratory, Department of Cardiology and Vascular Medicine, RSUD Pasar Rebo, East Jakarta, Indonesia.
Faculty of Medicine, Universitas Muhammadiyah Prof. DR. Hamka, Tangerang, Indonesia.
Med Pharm Rep. 2021 Jan;94(1):15-21. doi: 10.15386/mpr-1884. Epub 2021 Jan 29.
Heart failure (HF) and metabolic syndrome (MetS) are syndromes that affect a large proportion of the world population. MetS is known to be one of the risk factors of HF, and it can also act as comorbidity in HF. This review aims to further discuss the mechanism of MetS in causing HF, the management of MetS in order to prevent HF, and the management of MetS in HF patients. Visceral adiposity is the primary trigger of MetS which is followed by chronic inflammation, insulin resistance, and neurohormonal activation. All the mechanisms causing MetS play also an important role in the progression of HF. The MetS approach can be achieved by managing its components according to the current guidelines and careful management of MetS should be done in patients with HF. MetS is closely related to the progression of HF so that comprehensive management which involves a multidisciplinary team is necessary for managing patients with metabolic syndrome and heart failure.
心力衰竭（HF）和代谢综合征（MetS）是影响全球很大一部分人口的综合征。已知MetS是HF的危险因素之一，它也可作为HF的合并症。本综述旨在进一步讨论MetS导致HF的机制、为预防HF而对MetS的管理以及HF患者中MetS的管理。内脏肥胖是MetS的主要触发因素，其次是慢性炎症、胰岛素抵抗和神经激素激活。所有导致MetS的机制在HF的进展中也起重要作用。可以通过根据当前指南管理其组成部分来实现对MetS的处理，并且应对HF患者进行仔细的MetS管理。MetS与HF的进展密切相关，因此对于管理代谢综合征和心力衰竭患者，需要由多学科团队进行综合管理。
